10x Genomics Begins Commercial Shipments of Chromium GEM-X Products
PLEASANTON, Calif., March 13, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3. GEM-X is the next generation of the company's leading single cell technology architecture and is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized reagents for superior performance and high reliability.
- "It's been incredible to see the enthusiasm from customers since we first announced the GEM-X architecture last month, and we can't wait to get these new products in researchers' hands," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer of 10x Genomics.
- "GEM-X sets a new standard for single cell analysis and gives customers important performance advantages that will immediately benefit their research.
- This is one of multiple steps we have planned to make single cell more accessible for all."
- "GEM-X, with its exceptional transcript capture, can enhance our capacity to differentiate cell types, spot rare cells and decode regulatory pathways.